Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

Executive Summary

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

You may also be interested in...



More Small Biotechs Are Launching Drugs On Their Own

Emerging biopharma companies developed and launched 40% of all new drugs that hit the market in the US in 2020, a significant increase from five years ago, according to IQVIA.

Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?

In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry. 

Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel